Massimo Catarini
Impact in
- Hematology top 5%
- Multiple Myeloma Research and Treatments
-
- Cancer Treatment and Pharmacology
- Peptidase Inhibition and Analysis
Papers in
- Hematology 23
- Multiple Myeloma Research and Treatments 19
- Oncology 14
- Cancer Treatment and Pharmacology 7
- Peptidase Inhibition and Analysis 6
- Co-authors
- Massimo Offidani (22 shared papers)Laura Corvatta (21 shared papers)Francesco Alesiani (18 shared papers)Pietro Leoni (21 shared papers)Marino Brunori (17 shared papers)Giuseppe Visani (14 shared papers)Attilio Olivieri (8 shared papers)Mauro Montanari (6 shared papers)
In The Last Decade
Massimo Catarini
33 papers receiving 538 citations
Peers
Comparison fields: 5 of 61
- Hematology 334
- Oncology 203
- Genetics 64
- Geriatrics and Gerontology 20
- Pathology and Forensic Medicine 75
Countries citing papers authored by Massimo Catarini
This map shows the geographic impact of Massimo Catarini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Massimo Catarini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Massimo Catarini more than expected).
Fields of papers citing papers by Massimo Catarini
This network shows the impact of papers produced by Massimo Catarini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Massimo Catarini. The network helps show where Massimo Catarini may publish in the future.
Co-authors
The 25 scholars most cited alongside Massimo Catarini, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 34 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study. | 2006 | 65 |
| 2 | 2012 | 51 | |
| 3 | 2012 | 44 | |
| 4 | 2008 | 43 | |
| 5 | 2004 | 42 | |
| 6 | 2012 | 40 | |
| 7 | 2011 | 27 | |
| 8 | 2007 | 26 | |
| 9 | 2008 | 24 | |
| 10 | 2004 | 23 | |
| 11 | 2016 | 19 | |
| 12 | 2011 | 17 | |
| 13 | 2014 | 16 | |
| 14 | 2013 | 15 | |
| 15 | 2010 | 13 | |
| 16 | 2004 | 12 | |
| 17 | Thalidomide plus oral melphalan for advanced multiple myeloma: a phase II study. | 2003 | 10 |
| 18 | 2008 | 10 | |
| 19 | 1988 | 10 | |
| 20 | 2013 | 8 |
About Massimo Catarini
Massimo Catarini is a scholar working on Hematology, Oncology, Pathology and Forensic Medicine, Genetics and Molecular Biology, having authored 34 papers that have together received 551 indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (19 papers), Protein Degradation and Inhibitors (9 papers), Cancer Treatment and Pharmacology (7 papers), Peptidase Inhibition and Analysis (6 papers), Lymphoma Diagnosis and Treatment (4 papers), Acute Lymphoblastic Leukemia research (2 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (2 papers) and Histone Deacetylase Inhibitors Research (2 papers). The work is most often cited by research in Hematology (334 citations), Oncology (203 citations), Genetics (64 citations), Geriatrics and Gerontology (20 citations) and Pathology and Forensic Medicine (75 citations). Massimo Catarini has collaborated with scholars based in Italy, Poland and Brazil. Frequent co-authors include Massimo Offidani, Laura Corvatta, Francesco Alesiani, Pietro Leoni, Marino Brunori, Giuseppe Visani, Attilio Olivieri, Mauro Montanari, Riccardo Centurioni and Claudia Ambrosio Polloni. Their work appears in journals such as Blood, European Journal Of Haematology, British Journal of Haematology, Cancer and The American Journal of Cardiology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.